New 'Behçet's Spectrum Disorders' Framework Promises Faster Diagnosis for Children with Unexplained Inflammatory Symptoms

A new framework for understanding Behçet's disease (BD) and related inflammatory conditions in children could reduce diagnostic delays and guide targeted therapies, according to a review published in the World Journal of Pediatrics. Researchers from Peking Union Medical College Hospital in Beijing have formalized the concept of Behçet's spectrum disorders (BSD), first introduced in 2020, which groups together inflammatory conditions that share immune pathways with BD.

Behçet's disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but children often present with partial or atypical symptoms, making diagnosis difficult. Additionally, several monogenic autoinflammatory disorders produce nearly identical symptoms but require different treatments. The new BSD framework aims to address this diagnostic overlap by providing a mechanism-based classification rather than relying solely on symptom patterns.

The review, available at https://doi.org/10.1007/s12519-026-01035-4, proposes a two-tier system. "Core BSD" includes monogenic diseases that directly disrupt NF-κB or JAK-STAT signaling pathways, such as HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and converge on inflammatory circuits central to BD. "Peripheral BSD" encompasses polygenic or multifactorial conditions like recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease, which show partial clinical overlap but lack a single genetic driver.

The identification of NF-κB and JAK-STAT as common inflammatory hubs provides a rational basis for grouping these diverse disorders. The framework also delineates exclusion criteria to distinguish true spectrum members from phenotypic mimics such as LIG4 deficiency and IKBKG (NEMO) mutations, sharpening diagnostic boundaries. Importantly, the BSD framework does not replace existing BD diagnostic criteria but offers a mechanism-oriented lens to prioritize genetic testing in early-onset or atypical pediatric cases, potentially reducing diagnostic odysseys.

Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing for targeted therapies such as IL-1, TNF, or JAK inhibitors for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations. The authors emphasize that the framework is particularly valuable in children with recurrent mouth ulcers, fever, and gut inflammation that do not fully meet BD criteria.

"We're not saying these are all the same disease—they're not," the authors said. "But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why."

This biology-driven approach marks a shift from purely symptom-based classification to stratified, mechanism-informed nosology, empowering pediatricians to move towards precision medicine for children with complex, refractory inflammatory conditions.